Annual Secretarial Compliance Report for the Financial year ended March 31, 2025 under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements)
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has filed its Annual Secretarial Compliance Report for FY ending March 31, 2025, confirming overall compliance with SEBI regulations including LODR, Insider Trading, and related party transaction rules. All required policies are in place, the website and disclosures are up to date, and no director disqualifications were found. The company has no subsidiaries and there was no statutory auditor resignation during the year. The only notable item is a SEBI settlement order against promoter Mr. Rajpal Singh Kochhar, involving a Rs. 22.75 lakh penalty for inadvertent non-compliance with insider trading rules during Dec 2021 to March 2022 (related to trading window closure and digital database maintenance, not actual trading in company shares). The promoter has already paid the settlement amount, and the matter is closed.
This is a routine annual compliance disclosure with no material impact on the company's current operations or stock price. The promoter settlement relates to a historical procedural lapse (no actual share trading involved), and the penalty was paid by the promoter personally, so there is no financial burden on the company.